BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rusanov V, Kramer MR, Raviv Y, Medalion B, Guber A, Shitrit D. The Significance of Elevated Tumor Markers Among Patients With Idiopathic Pulmonary Fibrosis Before and After Lung Transplantation. Chest 2012;141:1047-54. [DOI: 10.1378/chest.11-0284] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang Q, Gao C, Zhang C, Yao M, Liang W, Sun W, Zheng Z. Tumor markers are associated with rapidly progressive interstitial lung disease in adult-dermatomyositis. Clin Rheumatol 2022. [PMID: 35138465 DOI: 10.1007/s10067-022-06089-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Majewski S, Szewczyk K, Żal A, Białas AJ, Miłkowska-Dymanowska J, Piotrowski WJ. Serial Measurements of Circulating KL-6, SP-D, MMP-7, CA19-9, CA-125, CCL18, and Periostin in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Therapy: An Exploratory Study. J Clin Med 2021;10:3864. [PMID: 34501312 DOI: 10.3390/jcm10173864] [Reference Citation Analysis]
3 Ballester B, Milara J, Montero P, Cortijo J. MUC16 Is Overexpressed in Idiopathic Pulmonary Fibrosis and Induces Fibrotic Responses Mediated by Transforming Growth Factor-β1 Canonical Pathway. Int J Mol Sci 2021;22:6502. [PMID: 34204432 DOI: 10.3390/ijms22126502] [Reference Citation Analysis]
4 Gomes PS, Soares MR, Marchenta MFML, Meirelles GSP, Ferreira RG, Botelho AB, Martins RB, Pereira CAC. Carbohydrate antigen 15-3 as a marker of disease severity in patients with chronic hypersensitivity pneumonitis. J Bras Pneumol 2021;47:e20200589. [PMID: 33681879 DOI: 10.36416/1806-3756/e20200589] [Reference Citation Analysis]
5 d'Alessandro M, Bergantini L, Torricelli E, Cameli P, Lavorini F, Pieroni M, Refini RM, Sestini P, Bargagli E. Systematic Review and Metanalysis of Oncomarkers in IPF Patients and Serial Changes of Oncomarkers in a Prospective Italian Real-Life Case Series. Cancers (Basel) 2021;13:539. [PMID: 33572642 DOI: 10.3390/cancers13030539] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Wahl TS, Wei B. Commentary: Embryonic Thoughts About CEA and Lung Transplant. Semin Thorac Cardiovasc Surg 2021;33:616-7. [PMID: 33181293 DOI: 10.1053/j.semtcvs.2020.10.044] [Reference Citation Analysis]
7 Balestro E, Castelli G, Bernardinello N, Cocconcelli E, Biondini D, Fracasso F, Rea F, Saetta M, Baraldo S, Spagnolo P. CA 19-9 serum levels in patients with end-stage idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs): Correlation with functional decline. Chron Respir Dis 2020;17:1479973120958428. [PMID: 32969271 DOI: 10.1177/1479973120958428] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Okabe R, Chen-Yoshikawa TF, Yoshizawa A, Nakajima N, Saito M, Hamaji M, Date H. Association Between Pretransplant Serum Carcinoembryonic Antigen Levels and Immunohistochemical Staining of Explanted Native Lungs in Patients Who Underwent Lung Transplantation. Semin Thorac Cardiovasc Surg 2021;33:608-15. [PMID: 32977009 DOI: 10.1053/j.semtcvs.2020.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Moll SA, Wiertz IA, Vorselaars AD, Zanen P, Ruven HJ, van Moorsel CH, Grutters JC. Serum biomarker CA 15-3 as predictor of response to antifibrotic treatment and survival in idiopathic pulmonary fibrosis. Biomark Med 2020;14:997-1007. [PMID: 32940077 DOI: 10.2217/bmm-2020-0165] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Moll SA, Wiertz IA, Vorselaars ADM, Ruven HJT, van Moorsel CHM, Grutters JC. Change in Serum Biomarker CA 15-3 as an Early Predictor of Response to Treatment and Survival in Hypersensitivity Pneumonitis. Lung 2020;198:385-93. [PMID: 31993739 DOI: 10.1007/s00408-020-00330-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Moua T, Lee AS, Ryu JH. Comparing effectiveness of prognostic tests in idiopathic pulmonary fibrosis. Expert Rev Respir Med 2019;13:993-1004. [PMID: 31405303 DOI: 10.1080/17476348.2019.1656069] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
12 Li B, Zhang X, Xu G, Zhang S, Song H, Yang K, Dai H, Wang C. Serum prealbumin is a prognostic indicator in idiopathic pulmonary fibrosis. Clin Respir J 2019;13:493-8. [PMID: 31102566 DOI: 10.1111/crj.13050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
13 Inchingolo R, Varone F, Sgalla G, Richeldi L. Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine 2018;13:39-51. [DOI: 10.1080/17476348.2019.1553620] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
14 Copur MS, Wurdeman JM, Nelson D, Ramaekers R, Gauchan D, Crockett D. Normalization of Elevated Tumor Marker CA27-29 After Bilateral Lung Transplantation in a Patient With Breast Cancer and Idiopathic Pulmonary Fibrosis. Oncol Res 2018;26:515-8. [PMID: 29229020 DOI: 10.3727/096504017X15128550060375] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
15 Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA, Flynn A, Molyneaux PL, Braybrooke R, Divyateja H, Parfrey H, Rassl D, Russell AM, Saini G, Renzoni EA, Duggan AM, Hubbard R, Wells AU, Lukey PT, Marshall RP, Jenkins RG. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med. 2017;5:946-955. [PMID: 29150411 DOI: 10.1016/s2213-2600(17)30430-7] [Cited by in Crossref: 91] [Cited by in F6Publishing: 36] [Article Influence: 18.2] [Reference Citation Analysis]
16 Spoorenberg SM, Vestjens SM, Rijkers GT, Meek B, van Moorsel CH, Grutters JC, Bos WJ; Ovidius Study Group. YKL-40, CCL18 and SP-D predict mortality in patients hospitalized with community-acquired pneumonia. Respirology 2017;22:542-50. [PMID: 27782361 DOI: 10.1111/resp.12924] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
17 Koch MC, Pereira IA, Nobre LF, Neves FS. Computed tomography of pulmonary changes in rheumatoid arthritis: carcinoembryonic antigen (CEA) as a marker of airway disease. Rheumatol Int 2016;36:531-9. [PMID: 26886389 DOI: 10.1007/s00296-016-3438-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J 2015;46:1113-30. [DOI: 10.1183/13993003.02316-2014] [Cited by in Crossref: 188] [Cited by in F6Publishing: 169] [Article Influence: 26.9] [Reference Citation Analysis]
19 Barouchos N, Papazafiropoulou A, Iacovidou N, Vrachnis N, Barouchos N, Armeniakou E, Dionyssopoulou V, Mathioudakis AG, Christopoulou E, Koltsida S, Bassiakou E. Comparison of tumor markers and inflammatory biomarkers in chronic obstructive pulmonary disease (COPD) exacerbations. Scand J Clin Lab Invest 2015;75:126-32. [PMID: 25598350 DOI: 10.3109/00365513.2014.992944] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
20 Kistler KD, Nalysnyk L, Rotella P, Esser D. Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulm Med 2014;14:139. [PMID: 25127540 DOI: 10.1186/1471-2466-14-139] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 9.4] [Reference Citation Analysis]
21 De Lauretis A, Renzoni EA. Molecular Biomarkers in Interstitial Lung Diseases. Mol Diagn Ther 2014;18:505-22. [DOI: 10.1007/s40291-014-0109-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
22 Dai H, Liu J, Liang L, Ban C, Jiang J, Liu Y, Ye Q, Wang C. Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers: Tumour markers in interstitial lung disease. Respirology 2014;19:707-13. [DOI: 10.1111/resp.12317] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
23 Fang SC, Zhang HT, Wang CY, Zhang YM. Serum CA125 and NSE: biomarkers of disease severity in patients with silicosis. Clin Chim Acta. 2014;433:123-127. [PMID: 24642341 DOI: 10.1016/j.cca.2014.03.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
24 Willemsen AE, Grutters JC, Gerritsen WR, Tol J, van Herpen CM. Caution for interstitial lung disease as a cause of CA 15-3 rise in advanced breast cancer patients treated with everolimus: Caution for Interstitial Lung Disease. Int J Cancer 2014;135:1007-1007. [DOI: 10.1002/ijc.28714] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
25 Celeste S, Santaniello A, Caronni M, Franchi J, Severino A, Scorza R, Beretta L. Carbohydrate antigen 15.3 as a serum biomarker of interstitial lung disease in systemic sclerosis patients. European Journal of Internal Medicine 2013;24:671-6. [DOI: 10.1016/j.ejim.2013.04.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]